BioCentury | Oct 8, 2020
Product Development

COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI

COVAX nearing $2B fund-raising goal for equitable vaccine distributionThe U.K., Canada, Germany, Italy and Sweden pledged $958 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC), which seeks to ensure equitable access to COVID-19...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | May 11, 2018

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
BioCentury | May 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

...stroke. University of Plymouth Distillery Therapeutics NMDA receptor NR2D subtype (GRIN2D) Biomarkers Cancer Prostate cancer ADAM metallopeptidase with thrombospondin type 1 motif 8 (ADAMTS8)...
BioCentury | Apr 25, 2018
Translation in Brief

Prostate prognosis

...In addition, 9 of the 97 genes had not been previously associated with any cancer: ADAM metallopeptidase with thrombospondin type 1 motif 8 (ADAMTS8)...
BioCentury | Mar 31, 2018

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
BioCentury | Jan 19, 2018
Clinical News

Galapagos reports Phase Ib data for GLPG1972 in OA

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported top-line data from a Phase Ib trial in 30 patients ages 50-75 with knee and/or hip osteoarthritis (OA) showing that three dose levels of once-daily oral GLPG1972 for four weeks...
BioCentury | Oct 3, 2017
Distillery Therapeutics


INDICATION: Musculoskeletal Mouse studies suggest activating ADAMTS1 could help treat muscle injury. In a mouse model of muscle injury, levels of ADAMTS1 were higher in the injured muscle than in the contralateral uninjured muscle. Also...
BioCentury | Sep 1, 2017
Company News

Servier gets rights to Galapagos' OA candidate

In July, Servier (Neuilly-sur-Seine, France) said it exercised its option for worldwide commercialization rights, excluding the U.S., to GLPG1972 (S201086) from Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG). Galapagos retains U.S. commercialization rights. Galapagos will receive a €6...
BioCentury | Jan 27, 2017
Clinical News

IdeS: Ph II discontinued

Hansa discontinued an open-label, U.K. Phase II trial evaluating a single IV dose of IdeS after preliminary data from 2 asymptomatic patients with acquired TTP showed a "non-favorable" risk-benefit profile. The company said that while...
Items per page:
1 - 10 of 21